Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | BLM | P54132 | 3/20 | 0.60 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9387178 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL31273785 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL8962050 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL9386346 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL9387343 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL9390750 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL9387197 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL5955499 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL513074 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 | |
| SCHEMBL513056 | 1.00 | APP (0.79) | APPLMNABLMSLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994002497-A1 | SULFO-DERIVATIVES OF ADENOSINE | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-02-03 | — | — | WO | claimed |
| CN-103623741-B | Graphene dispersing agent, preparation method thereof and preparation method of graphene | CHANGCHUN APPLIED CHEMISTRY | 2015-05-20 | — | — | CN | disclosed |
| US-7074387-B2 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AG (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20030202943-A1 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-6565830-B1 | Contrast agent for imaging | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-6287538-B1 | CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
| US-5859214-A | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SCHERING AKTIENGESELLSHAFT (DE) | 1999-01-12 | — | — | US | disclosed |
| US-5843399-A | DTPA monoamides for MRI | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-01 | — | — | US | disclosed |
| EP-0450742-B1 | DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AG (DE) | 1994-07-06 | — | — | EP | disclosed |
| EP-0450742-A1 | DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030202943-A1 | DTPA monoamides, pharmaceutical agents containing these compounds, their use and process for their production | SLC43A1, HRH4, ACSL6 | APP 3486/4885LMNA 1863/4885BLM 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.